IP Library › Granted Patent US 11,208,659
Granted Patent B2
US 11,208,659 · App. 17/307,369 · Granted Dec 28, 2021

Pig with a genetically modified CD163 gene resistant to PRRSv

Inventors: Andrew Mark Cigan (Madison, WI); Jonathan Edward Lightner (Jefferson, WI); Matthew Scott Culbertson (Wilmington, NC); William Thomas Christianson (Hendersonville, TN); Benjamin Beaton (DeForest, WI); Brian Burger (Madison, WI); Dylan Barnes (Madison, WI); Matthew Campbell (Madison, WI)
Assignee: Genus PLC
C12N15/113A01K67/0275C12N9/22C12N15/8778A01K2217/052A01K2227/108C12N2310/20C12N2320/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,208,659
App. No.
17/307,369
Granted
Dec 28, 2021
Kind
B2
Abstract

The present disclosure relates methods and compositions useful for prevention of porcine reproductive and respiratory syndrome virus (PRRSv) in animals, including animals of the species Sus scrofa . The present teachings relate to swine wherein at least one allele of a CD163 gene has been inactivated, and to specific methods and nucleic acid sequences used in gene editing to inactivate the CD163 gene. Swine wherein both alleles of the CD163 gene are inactivated are resistant to porcine reproductive and respiratory syndrome virus (PRRSv). Elite lines comprising homozygous CD163 edited genes retain their superior properties.

Claims (19)

1. A transgenic Sus scrofa whose genome comprises a homozygous deletion of exon 7 of an endogenous CD163 gene, wherein the genetically modified CD163 gene comprises the nucleic acid sequence of SEQ ID NO: 453, and wherein the Sus scrofa is resistant to porcine reproductive and respiratory syndrome (PRRSV).

2. The genetically modified Sus scrofa of claim 1 , wherein the Sus scrofa has the genome of a cell line deposited under ATCC accession number PTA-125814, PTA-125815, PTA-125816, PTA-125811, PTA-125907, PTA-125812, or PTA-125813.

3. A cell isolated from the Sus scrofa of claim 1 .

4. An isolated cell line obtained from the Sus scrofa of claim 1 .

5. An isolated fibroblast cell line obtained from the Sus scrofa of claim 1 .

6. An isolated nucleic acid sequence encoding Sus scrofa CD163 with a deletion in exon 7, wherein the nucleic acid sequence comprises the nucleotide sequence of SEQ ID NO: 453 and is capable of conferring resistance to porcine reproductive and respiratory syndrome (PRRSV) in Sus scrofa.

7. An isolated cell whose genome comprises the nucleic acid sequence of claim 6 .

8. A cell line comprising a plurality of the isolated cell of claim 7 .

9. The cell line of claim 8 , wherein the isolated cell is a fibroblast.

10. The isolated cell of claim 7 , wherein the cell is deposited under ATCC accession number PTA-125814, PTA-125815, PTA-125816, PTA-125811, PTA-125907, PTA-125812, or PTA-125813.

11. A pair of guide RNAs (gRNAs) for editing a Sus scrofa CD163 gene comprising:

a gRNA comprising a guide sequence consisting of the nucleic acid sequence of SEQ ID NO: 249; and

a gRNA comprising a guide sequence consisting of the nucleic acid sequence of SEQ ID NO: 256.

12. A method of making a Sus scrofa that is resistant to porcine reproductive and respiratory syndrome virus (PRRSV), the method comprising:

a) introducing Cas9 and a pair of gRNAs consisting of the nucleic acid sequences of SEQ ID NO: 249 and 256 into an isolated Sus scrofa zygote such that a zygote is created whose genome comprises a homozygous deletion of exon 7 of an endogenous CD163 gene, wherein the CD163 gene comprises the nucleic acid sequence of SEQ ID NO: 453;

b) implanting the zygote obtained in step a) into a recipient female such that a Sus scrofa is obtained from the implanted zygote, wherein the Sus scrofa obtained from the implanting has a genome comprising a genetically modified homozygous deletion of exon 7 of an endogenous CD163 gene, has a CD163 gene comprising the nucleic acid sequence of SEQ ID NO: 453, and is resistant to PRRSV.

13. The method of claim 12 , wherein the method comprises administering Cas9, a gRNA comprising a guide sequence consisting of the nucleic acid sequence of SEQ ID NO: 249; and a gRNA comprising a guide sequence consisting of the nucleic acid sequence of SEQ ID NO: 256.

14. The method according to claim 12 , wherein the Cas9 and the gRNAs are introduced as a pre-formed ribonucleoprotein (RNP) complex.

15. The method of claim 12 , wherein the Sus scrofa obtained from the implanting has the genome of a cell line deposited under ATCC accession number PTA-125814, PTA-125815, PTA-125816, PTA-125811, PTA-125907, PTA-125812, or PTA-125813.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 4, 2021
From: BARNES, DYLAN; CAMPBELL, MATTHEW
To: GENUS PLC
Reel/Frame 056131/0820 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 4, 2021
From: BEATON, BENJAMIN; BURGER, BRIAN
To: GENUS PLC
Reel/Frame 056132/0079 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 4, 2021
From: CIGAN, ANDREW MARK; LIGHTNER, JONATHAN EDWARD; CULBERTSON, MATTHEW SCOTT; CHRISTIANSON, WILLIAM THOMAS
To: GENUS PLC
Reel/Frame 056132/0097 →
Continuity (3)
Provisional Application 63021370 · May 7, 2020
Provisional Application 63020128 · May 5, 2020
Related Publication 20210348165A1 · Nov 11, 2021
Cited By (2)
US 12,371,692 US 12,416,005